Skip to main content

ValiRx attends Biotech Outsourcing Strategies 2022

21 Nov 2022


ValiRx’s CEO Dr Suzy Dilly was pleased to attend Biotech Outsourcing Strategies (BOS) in Manchester last week, where she chaired a session focused on technical operations and contributed to a panel discussion about the trends shaping pharmaceutical outsourcing.

Launched in 2006 by Bio2Business, the Biotech Outsourcing Strategies events bring together stakeholders in R&D outsourcing to share experiences, build existing outsourcing partnerships, and forge new buyer/supplier business relationships.

BOS Manchester 2022 covered the outsourcing of discovery, small molecule CMC, and biologics. Representing ValiRx at the event, Suzy networked with fellow industry professionals and attended presentations about outsourcing and R&D trends and developments.

Suzy said: “The technical operations session I chaired was a pertinent topic for ValiRx and attracted some enthusiastic speakers who presented the challenges of the contract research organisation (CRO) world from both sides and discussed potential ways to build stronger partnerships between CROs and biotechs, to complete the scientific work in the most efficient manner. 

“It was also great to contribute to the panel session and discuss the main challenges facing the biotech industry alongside speakers from big pharma and service providers. Sustainability was a key issue raised in the discussion, along with the need for strong communication, between both industry collaborators and the public.”

For more information about BOS, click here.

Suzy Presenting at BOS Manchester 2022